China is one of the pharmaceutical manufacturing hubs globally. Its pharmaceutical industry garnered a total revenue of about 2.6 trillion yuan in 2019 amounting to an eight percent year-on-year growth. Between 2013 to 2019, there were 244 new types of class I drug ingredients that were applied in the National Medical Products Administration of China from domestic pharmaceutical companies. These new drug ingredients included 144 from chemical medicines and 100 from biological medicines. There was a significant increase in 2016 due to changes in policies announced by the National Medical Products Administration of China to boost the regulatory process of new drugs.
With is fast expanding ageing population, China has enhanced its pharmaceutical industry rapidly to meet growing demands. Even with the recent COVID-19 pandemic that started in late 2019, when China was one of the early epicentres, its pharmaceutical industry has continued to thrive. The quality and quantity of health care equipment and medical supplies products have improved a lot, which brought vitality to medical supplies companies in China. Instrumentation in pharmaceutical industry in China is also booming. In this article is a consolidated list of the nine largest Chinese pharmaceutical companies listed by market value, based on the Forbes Global 2000 annual ranking as of May 2020.
Jiangsu Hengrui Medicine
Market Value: US$ 58 billion
The pharmaceutical and health enterprise was founded in 1970. It was listed in the Shanghai Stock Exchange in the year 2000. Jiangsu Hengrui is one of the largest publicly listed biopharma companies based in China. It has more than 21,000 employees and 3,200 scientists working together in research and development across more than 30 programs in oncology, anaesthesiology and pain management, autoimmune disease, metabolic disease and cardiovascular disease.
Most recently in July 2020, Hengrui Therapeutics, Inc. (HTI) a U.S. subsidiary of Jiangsu Hengrui Medicine signed an agreement with Thermo Fisher Scientific in developing a companion diagnostic making use of the Oncomine Precision Assay for treatment decision-making. The assay will identify non-small cell lung cancer patients who could be eligible for pyrotinib an irreversible pan-HER2 tyrosine Kinase inhibitor newly developed by Jiangsu Hengrui Medicine.
Hansoh Pharmaceutical Group
Market Value: US$ 23 billion
Hansoh Pharmaceutical Group was founded in 1995 as a R&D-driven pharmaceutical company in China. Its more than 20 years of research and development has brought innovation to a number of therapeutic areas, namely, oncology, neurology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. With two research and development centres in Lianyungang and Shanghai, together with more than 1,200 employees, it has made significant contribution to unmet clinical needs in China.
In May 2019, Hansoh Pharmaceutical Group received National Drug Administration (NDA) approval from the National Medical Products Administration of China for its Polyethlyene Glycol Loxenatide injection for treatment of Type 2 Diabetes.
Yunnan Baiyao Group
Market Value: US$ 16.4 billion
Listed on the Shenzhen Stock Exchange, Yunnan Baiyao Group Co. Ltd was formerly known as the Yunnan Baiyao Factory founded in June 1971. It was not until October 1996, when the company was renamed to be Yunnan Baiyao Group Co., Ltd. The company is involved in the development, production and marketing of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese traditional medicines, biological products, health food, cosmetics, beverages, and medical devices, such as Class II and medical dressings.
Shanghai Fosun Pharmaceutical
Market Value: US$ 9.8 billion
Shanghai Fosun Pharmaceutical, also known as Fosun Pharma, was founded in 1994 and is listed in the Hong Kong, S.A.R., China Stock...
(All Rights Reserved)